Eyenovia Inc. They are dedicated to creating transformative therapies for progressive myopia, presbyopia, and mydriasis. Eyenovia's innovative Optejet® dispenser revolutionizes the way eye medications are administered.

This dispenser delivers precise, minimal amounts of medication horizontally to the eye, offering similar efficacy to traditional eyedropper treatments. The Optejet® has the potential to be equipped with Bluetooth capability, enabling easy patient compliance and adherence tracking. With the Optejet®'s microdosing technology, there is a reduction in systemic exposure and toxicity compared to traditional eyedroppers, which may result in a better tolerability and safety profile for patients.

Eyenovia's ultimate goal is to develop ophthalmic drug delivery technologies that are more effective, safer, and smarter than conventional methods. Eyenovia recently acquired the U. S.

They plan to evaluate novel clobetasol formulations in their Optejet® dispensing platform for the treatment of dry eye. Stay up to date with Eyenovia's latest news and advancements in their pipeline of therapies for various eye conditions